

RESEARCH ARTICLE

Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization

Danielle McAnally^{1,2}, Khandaker Siddiquee¹, Ahmed Gomaa³, Andras Szabo¹, Stefan Vasile², Patrick R. Maloney², Daniela B. Divlianska², Satyamaheshwar Peddibhotla², Camilo J. Morfa², Paul Hershberger², Rebecca Falter², Robert Williamson², David B. Terry², Rafal Farjo⁴, Anthony B. Pinkerton⁵, Xiaping Qi^{3,6}, Judith Quigley³, Michael E. Boulton^{3,6}, Maria B. Grant^{3,6}, Layton H. Smith^{1,2*}

1 Cardiovascular Pathobiology Program, Diabetes and Obesity Research Center, Sanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, United States of America, **2** Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, United States of America, **3** Department of Ophthalmology, Indiana University School of Medicine Indianapolis, Indiana, United States of America, **4** EyeCRO LLC, Oklahoma City, Oklahoma, United States of America, **5** Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States of America, **6** Department of Ophthalmology, University of Alabama, Birmingham, Alabama, United States of America

* lhsmith@sbpdiscovery.org



OPEN ACCESS

Citation: McAnally D, Siddiquee K, Gomaa A, Szabo A, Vasile S, Maloney PR, et al. (2018) Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. PLoS ONE 13(9): e0202436. <https://doi.org/10.1371/journal.pone.0202436>

Editor: Jing Chen, Children's Hospital Boston, UNITED STATES

Received: April 2, 2018

Accepted: August 2, 2018

Published: September 12, 2018

Copyright: © 2018 McAnally et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information file.

Funding: This work was funded by the Juvenile Diabetes Research Foundation (2-SRA-2014-146-Q-R), Florida Department of Health James and Esther King grant (4KF01), NIH NS059422, EY018358, EY028861 and HG005033. L.H.S. acknowledges support from the Florida Translational Research Program (COHK8), a contract administered by the Florida Department of

Abstract

Neovascularization is the pathological driver of blinding eye diseases such as retinopathy of prematurity, proliferative diabetic retinopathy, and wet age-related macular degeneration. The loss of vision resulting from these diseases significantly impacts the productivity and quality of life of patients, and represents a substantial burden on the health care system. Current standard of care includes biologics that target vascular endothelial growth factor (VEGF), a key mediator of neovascularization. While anti-VEGF therapies have been successful, up to 30% of patients are non-responsive. Therefore, there is a need for new therapeutic targets, and small molecule inhibitors of angiogenesis to complement existing treatments. Apelin and its receptor have recently been shown to play a key role in both developmental and pathological angiogenesis in the eye. Through a cell-based high-throughput screen, we identified 4-aminoquinoline antimalarial drugs as potent selective antagonists of APJ. The prototypical 4-aminoquinoline, amodiaquine was found to be a selective, non-competitive APJ antagonist that inhibited apelin signaling in a concentration-dependent manner. Additionally, amodiaquine suppressed both apelin- and VEGF-induced endothelial tube formation. Intravitreal amodiaquine significantly reduced choroidal neovascularization (CNV) lesion volume in the laser-induced CNV mouse model, and showed no signs of ocular toxicity at the highest doses tested. This work firmly establishes APJ as a novel, chemically tractable therapeutic target for the treatment of ocular neovascularization, and that amodiaquine is a potential candidate for repurposing and further toxicological, and pharmacokinetic evaluation in the clinic.

Health, and for which L.H.S. is the Principal Investigator. The funders provided support in the form of salaries for authors [D.M., K.S., A.G., S.V., P.R.M., D.B.D., S.P., C.J.M., P.H., R.F., R.W., D.B.T., A.B.P., X.Q., J.Q., M.E.B., M.B.G., L.H.S.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Rafal Farjo is an employee of EyeCRO, LLC. He provided subject matter expertise and his team provided contract research services on a fee-for-service basis. No employee of EyeCRO had any input regarding the interpretation of data, decision to publish, or preparation of the manuscript. This commercial affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials. The specific roles of these authors are articulated in the 'author contributions' section.

Competing interests: A patent covering the use of the compounds for pathological angiogenesis was submitted to the USPTO ("4-aminoquinoline compounds for the treatment of angiogenesis"; filed March 6, 2018; application number 62/639,291). This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Introduction

Two of the leading causes of visual impairment and blindness in the western world are diabetic retinopathy (DR) and exudative age-related macular degeneration (AMD) [1]. Both represent a significant impact on the independence, productivity and quality of life of patients as well as a substantial burden on the health care system. In 2010, more than 6 million Americans suffered from DR and ~2 million suffered from AMD, and the incidence is increasing significantly [2,3,4]. By 2050 the number of Americans with DR and AMD are expected to double [4]. As the lifespan of our population continues to increase, there will be an increasing number of people who are at risk of developing visual impairment. Consequently, the economic burden of visual impairment will continue to grow.

Over the last 15 years, significant advances have been made in the understanding of both DR and AMD. It is now clear that pathological angiogenesis (or neovascularization) contributes to the loss of vision by causing hemorrhage; fibrosis; retinal detachment; and vascular leakage, leading to edema and the deposition of drusen within the retina. Vascular endothelial growth factor (VEGF) plays a key role in this pathophysiology and is the target of current FDA-approved antiangiogenic protein therapeutics [5,6,7,8]. Ranibizumab (Lucentis; Genentech/Roche) [9,10,11], bevacizumab (Avastin; Genentech/Roche) [12,13,14,15] and aflibercept (Eylea; Regeneron Pharmaceuticals)—all anti-VEGF agents—are currently the most common therapies for neovascular AMD. While these therapies have been highly effective, recent studies show a decline in long-term efficacy, which is believed to result from the emergence of VEGF-independent mechanisms and expression of other growth factors and cytokines involved in maintaining the abnormal angiogenic milieu [16,17]. In addition, the further decline in visual function with long-term anti-VEGF therapy has been linked to the loss of the choroidal blood supply, which is in part VEGF-dependent and which supports the integrity and health of the overlying retinal pigment epithelium and neural retina [18,19,20]. Moreover, a significant number of patients receiving anti-VEGF therapies do not benefit and vision continues to diminish [21,22]. The options for these patients are limited. Therefore there is a critical need to target other receptors linked to pathologic neovascularization as an alternative or adjunctive approach to approved anti-VEGF treatments.

Apelin is a peptide hormone recently identified as the endogenous ligand of the APJ receptor [23,24,25] formerly recognized as an orphan G-protein coupled receptor (GPCR). A single gene encodes the pre-pro-apelin protein. Sequential N-terminal deletions produce at least four biologically active apelin peptides: apelin-36, apelin-17, apelin-13 and apelin-12 [26,27]. All apelin peptides are inactivated by removal of the C-terminal phenylalanine residue, catalyzed by the angiotensin converting enzyme 2 (ACE-2) [28]. These four apelin peptides bind and activate APJ [24,29], a GPCR that has been shown to signal via G α i and ERK pathways [30]. Apelin and APJ are expressed in an array of tissues, and regulate a variety of processes including cardiovascular homeostasis [31,32,33,34,35], food intake [36,37], fluid balance [38,39,40] and cellular proliferation [41,42,43].

While most studies have focused on the cardiovascular effects of apelin, a few have explored its role in both physiological and pathological angiogenesis in the eye [44,45]. Apelin enhances migration, proliferation, and capillary-like tube formation of retinal endothelial cells (RF/6A), but not umbilical vein endothelial cells (HUVEC) [45]. *In vivo*, apelin contributes to retinal vascularization and normal ocular development [46,47], as well as pathological angiogenesis [48,49,50]. Although the precise process by which apelin/APJ promotes retinal angiogenesis is unknown, it is clear that the apelin/APJ system acts synergistically with VEGF via discrete mechanisms to promote vascular development [45,46,47,49,51,52,53,54,55].

Using an existing cell-based assay of APJ signaling [56,57], we screened the Sanford Burnham Prebys (SBP) compound collection of drug-like compounds to identify novel APJ antagonists. We identified multiple compounds that blocked apelin-dependent activation of APJ, including a series of 4-aminoquinolines. The antimalarial compound amodiaquine contains a substituted aminoquinoline core, and was purchased as part of our initial exploration of the structure-activity-relationship between this scaffold and APJ. Amodiaquine antagonized APJ and blocked apelin-induced endothelial tube formation *in vitro*. Further *in vivo* studies in a mouse model of choroidal neovascularization confirmed the antiangiogenic effects of amodiaquine. Mechanistic investigations revealed that amodiaquine acts as a non-competitive inhibitor of apelin-mediated APJ activation. This study, along with a recent report published during the preparation of this manuscript [58], validate small-molecule modulation of APJ as a therapeutic strategy to prevent pathologic angiogenesis in the eye.

Results

Identification and validation of aminoquinolines as APJ antagonists

To identify small-molecule antagonists of the apelin receptor (APJ) we interrogated the SBP compound file of ~425,000 compounds using CHO-k1-AGTRL1 cells overexpressing human APJ and a competitive immunoassay of intracellular cAMP [59]. The compound file was screened at a concentration of 10 μ M. For all 333 plates assayed, the average Z-factor = 0.68 and the average S/B = 8.2, indicating a robust assay performance. Active compounds were those that inhibited Ap13 (1.0 nM)-mediated decrease in forskolin stimulated intracellular cAMP by $\geq 50\%$. There were 2550 compounds that met this criterion, representing a hit rate of ~0.6%. Fig 1A shows a scatter plot of the screening data. Included in this hit set was a series of aminoquinolines, exemplified by compound 1 (Fig 1B). A substructure similarity search of the SciFinder database revealed that 1 shared a common 4-chloro-aminoquinoline core with two approved drugs, amodiaquine (2, hereafter AQ) and glafenine (3). As part of an initial hit-validation strategy, these compounds and three other commercially available analogs were purchased for further testing. The purity and identify of all compounds were confirmed by NMR and LC-MS, and they were subsequently retested in a battery of cell-based assays of APJ function and counter screens. When tested in the primary APJ cAMP assay, all six aminoquinolines were found to be potent APJ antagonists (Fig 1C and 1D). When tested in cells lacking the receptor (parental CHO-K1) or in those expressing the closely related angiotensin II type 1 (AT1) [60], all six compounds demonstrated selectivity for APJ. Interestingly, neither AQ nor 1, 3, 4, 5, or 6 antagonized Ap13-mediated recruitment of β -arrestin suggesting a selective, or biased, antagonism [61] of G-protein-dependent signaling by APJ. None of the compounds exhibited cytotoxicity when tested on Fa2-N4 hepatocytes at concentrations up to 50 μ M. (Fig 1D). Compared to the aminoquinoline compounds shown in Fig 1, AQ was chosen for potential repurposing for the following reasons: 1) AQ is often used as both a prophylactic and a treatment for *Plasmodium falciparum* infection and has fewer, less severe side effects than 3 (glafenine); 2) although some analogs were more potent, these compounds have not been used in humans and thus were not suitable for a repurposing strategy, and 3) the potential for further structural modification to increase APJ antagonism and reduce side-effects.

To better characterize the mechanism by which AQ antagonizes APJ, and determine the potency of the antagonism, we next tested the ability of AQ to decrease the EC₅₀ of Ap13. AQ failed to produce parallel shifts in the concentration response curves for Ap13. At concentrations above 2.4 μ M, AQ shifted the EC₅₀ of Ap13 and reduced E_{max} correspondingly (Fig 2A). At higher concentrations, AQ virtually eliminated all response to Ap13. The pA2 could not be calculated because the assumptions of the Schild analysis were not met [62]. Consistent with




Fig 1. HTS for APJ antagonists and hit confirmation of 4-aminoquinoline analogs. (A) Scatter plot of the hits and controls from the HTS. Activity (%) was calculated by normalizing luminescence signal to the mean signal in the dimethyl sulfoxide (DMSO) wells. Compounds were considered hits if they inhibited the response to Ap13 (1 nM) by $\geq 40\%$. (B) Chemical structures of 4-amino-quinolines (4AQs) and (C) concentration response curves for hits and analogs. The percent inhibition of 1nM Ap13 is shown. The inset table (D) shows the IC_{50} s of the 4AQs in the primary APJ assay (cAMP), secondary assay (APJ β -arrestin recruitment) and counter assays (AT1 β -arrestin recruitment, and parental cells (cells lacking APJ) cAMP). General cytotoxicity was assessed using ATP-lite assay and Fa2-N4 cells as described. All IC_{50} data are reported in μ M. Data are means \pm SEM ($n = 3$). Curves represent the best fit non-linear regression analysis calculated using a 4-parameter logistic with GraphPad Prism7.

<https://doi.org/10.1371/journal.pone.0202436.g001>

these functional results, AQ did not displace [125 I]-Glp65, Nle75, Tyr7-Ap13 binding to membranes containing APJ when tested as high as 100 μ M. In contrast, unlabeled Ap13 and the prototypical APJ antagonist ML221 [57] effectively displaced [125 I]-Glp65, Nle75, Tyr7-Ap13 with $K_i = 0.18$ nM and 1.33 μ M respectively (Fig 2B). Taken together, these data indicate that AQ is a non-competitive APJ antagonist.

Anti-angiogenic activities of APJ antagonists

We next sought to determine the effect of AQ on the proliferation and migration of human retinal microvascular endothelial cells (HRECs). Previous studies have reported that endothelial cells derived from multiple distinct vascular beds express APJ and respond to Ap13 [45,49,63,64,65]. However, there are no published studies in which APJ expression has been confirmed in HRECs. Therefore, we applied immunohistologic and western blotting approaches to confirm endogenous expression of APJ in these cells. A polyclonal antibody targeting the intracellular C-terminal tail of human APJ and a fluorescently conjugated secondary detection antibody, identified APJ immunoreactivity throughout the cell in a generally diffuse speckled pattern (Fig 3A). APJ immunoreactivity was not evenly distributed; it appeared to be enriched around the nucleus. This is likely reflective of the morphology of the HREC where the nucleus constitutes the thickest part of the cell. This staining pattern is consistent with that




Fig 2. AQ is a non-competitive apelin receptor antagonist. (A) Ap13 concentration response curves showing the effect of pre-incubation either in the absence (○) or with different concentrations of AQ for 0.5h at 37°C: 0.3 μM (red ×), 2.4 μM (green △), 19.7 μM (purple ▼), 157.4 μM (orange ◆), after which increasing concentrations of Ap13 were added and the incubation continued for 0.5h. AQ reduced the E_{max} of Ap13 responses, reflecting insurmountable inhibition. Data are mean ± SEM ($n = 3$). (B) Radioligand binding inhibition curves showing percent bound [¹²⁵I]-Glp65, Nle75, Tyr77-Ap13 with different concentrations of cold, unlabeled Ap13 (green △), and the competitive apelin receptor antagonist ML221 (blue •) and AQ (red ■). Data shown are the mean ± SEM of two independent experiments ($n = 2$) with each data point performed in duplicate. All curves overlaying the data points represent the best fit line of non-linear regression analysis performed as described in Materials and Methods.

<https://doi.org/10.1371/journal.pone.0202436.g002>

previously reported for APJ in HUVECs [65], rhesus choroid endothelial cells [49] and retinal pericytes [66], as well as other GPCRs [67]. APJ immunoreactivity in HRECs was specific (Fig 3B), and was confirmed using three additional APJ antibodies targeting other epitopes within the protein, and qPCR (Figure A and Table A in S1 File). The cytosolic, nuclear and membrane fractions of HRECs were subjected to western blotting using the same antibody. APJ immunoreactivity was highly enriched in the membrane fraction, but not the cytosolic or nuclear fractions. A single band of slightly less than 49 kD was observed. This molecular weight is consistent with a predicted APJ molecular weight of ~43 kD. The efficiency of the cellular fractionation method was monitored by blotting for the membrane bound Na/K ATPase and nuclear laminin (Fig 3C). When HRECs were incubated with Ap13 (1.0 nM) for 60 min, the pattern of APJ immunoreactivity shifted from a diffuse speckled pattern to one characterized by aggregated bright puncta (Fig 3D and 3E), indicating that the addition of ligand coalesced APJ immunoreactivity into pits characteristic of activated GPCRs [68,69].

Having confirmed that HREC cells express APJ, we next evaluated the effect of Ap13 and its inhibitors on HREC proliferation, migration and tube formation. As expected, the proangiogenic VEGF (100 ng/mL) stimulated HREC proliferation and migration (Fig 4A and 4B). In contrast, Ap13 had no significant effect on either proliferation or migration of HRECs (Fig 4A and 4B). Both VEGF and Ap13 stimulated the formation of endothelial tubes. When tested at multiple concentrations, Ap13 increased overall tube length in a concentration-dependent manner that was equivalent or greater than VEGF (Fig 4C). The combination of Ap13 with VEGF did not significantly increase the extent of tube formation formed when either factor




Fig 3. Human retinal endothelial cells (HREC) express APJ. (A) APJ protein was detected and visualized in HRECs by immunocytochemistry using the anti-APJ antibody ab140508, and Alexa488 conjugated secondary antibody. (B) A control experiment in which the primary anti-APJ antibody was omitted shows the specificity of APJ immunoreactivity. (C, D) Incubation of HRECs with Ap13 (1 nM) led to the aggregation of APJ immunoreactivity into bright puncta after 60 min. Cell images are maximal intensity projections taken using a confocal microscope and pseudocolored for ease of interpretation. APJ is shown in yellow or white. Nuclei were visualized using DAPI and colored blue. (E) Cytosolic (c), membrane (m) and nuclear (n) fractions of HREC cells were isolated and subjected to SDS-PAGE and Western blotting as described. APJ (green band indicated by a white triangle on the right of the image) immunoreactivity was observed only in the membrane fraction with a migration of < 49 kDa. The efficiency of the cellular fractionation was monitored by blotting for the membrane bound Na/KATPase (top bracket on right) and nuclear laminin (bottom bracket on right), both shown in red. St = molecular weight marker.

<https://doi.org/10.1371/journal.pone.0202436.g003>

was added alone, indicating that Ap13 and VEGF do not act synergistically on HRECs (Figure B in S1 File).

Both AQ and the prototypical APJ antagonist M221 blocked Ap13-dependent increases in tube formation. For both compounds this effect was concentration-dependent (Fig 4D and 4E). In order to clarify the relationship between apelin and VEGF in this system, and to test the hypothesis that AQ antagonizes HREC tube formation independent of VEGF signaling, we examined the effect of AQ on VEGF-induced tube formation. In the absence of exogenous Ap13, AQ blocked VEGF-induced tube formation (Fig 4F). A similar effect was observed for ML221 (Figure C in S1 File), indicating that the opposition to VEGF-induced tube formation was mediated by the selective antagonism of APJ by AQ and ML221. This effect was sufficiently pronounced that it decreased the overall tube length compared to vehicle. We performed a cell viability assay on HRECs to ensure that this observation was not reflective of cytotoxicity. Neither ML221 nor AQ were significantly toxic to HRECs (Table 1) when tested up to 100 μ M.

***In vitro* ADME and tissue distribution of amodiaquine**

To determine the suitability of the compound for use in *in vivo* efficacy studies, the ADME/T (absorption, distribution, metabolism, excretion, and toxicity) and pharmacokinetic properties




Fig 4. Effects of Ap13 on HREC proliferation, migration and tube formation. (A) Proliferation: human retinal endothelial cells (HRECs) were exposed to vehicle (DMSO 1% v/v), VEGF (100 ng/mL), and Ap13 (10 nM) for 16 h. Proliferation was determined as described in Material and Methods. (B) Migration. Data plotted is the mean percent (%) change \pm SEM normalized to vehicle control. NS = not significant; ** = $p < 0.01$; *** = $p < 0.001$ vs vehicle; as determined by ANOVA with Dunnett's test for comparison to control. (C) Ap13 induces HREC tubular network formation *in vitro*. (D, E) The prototypical APJ antagonists ML221 and AQ block Ap13-induced HREC tube formation in a concentration dependent manner. (F) AQ blocks VEGF-induced HREC tube formation in a concentration dependent manner. Data plotted is the mean \pm SEM length of endothelial tubes measured in micrometers (μm), normalized to vehicle control. Mean and SEM are calculated from an experiment that was performed twice with each treatment condition tested in triplicate ($n = 3$). NS = not significant; ** = $p < 0.01$; *** = $p < 0.001$ vs vehicle; † = $p < 0.0001$ compared to cells exposed to VEGF alone (100 ng/mL) as determined by ANOVA with Tukey's multiple comparison test.

<https://doi.org/10.1371/journal.pone.0202436.g004>

of AQ were evaluated (Table 1). At physiological pH (7.4), the LogD of AQ is optimal. Accordingly, AQ was moderately soluble in aqueous media and exhibited moderate permeability in the PAMPA assay. Plasma protein binding (<90% bound) and stability (>25% remaining at $t = 3$ h) were within the acceptable range [70,71]. In human microsomes, AQ exhibited a two-

Table 1. Profile of AQ absorption, distribution, metabolism, elimination and toxicity (ADME/T).

Compound		AQ (2)
Polar surface area (A ² , calculated by ChemBioDraw)		47.86
CLogP		5.46
LogD (pH 7.4)		2.37
Aqueous solubility (µg/mL) pH 5.0 / 6.2 / 7.4		>35 / > 48 / 17
PAMPA permeability Pe (x10 ⁻⁶ cm/s) Donor pH: 5.0/ 6.2/7.4; Acceptor pH: 7.4		3.0 / 9.6 / 54.0
Plasma-protein binding (% bound)	Human 1 µM / 10 µM	88.2 / 83.8
	Mouse 1 µM / 10 µM	81.9 / 70.8
	Rat 1 µM / 10 µM	75.3 / 76.8
Plasma stability (% remaining at 3 hrs) Human / Mouse / Rat		37.3 / 36.1 / 46.3
Hepatic microsome stability T1/2 (min) Human / Mouse / Rat		17.0* / 39.8 / 38.9
Cytotoxicity LC ₅₀ (µM)	Fa2N-4 cells	> 50
	HRECs	> 100

<https://doi.org/10.1371/journal.pone.0202436.t001>

phase exponential decay with a terminal half-life of 17.0 min. In rats and mouse hepatic microsomes, AQ exhibited a slower rate of decay best described as a single phase with a half-life of 38.9 and 39.8 min respectively (Figure D in [S1 File](#)). The primary metabolite of AQ is a desethyl form resulting from CYP450 metabolism [72]. Thus it is not surprising that AQ was rapidly metabolized by human, mouse and rat liver microsomes. Indeed, the metabolism of AQ coincided with the appearance of the desethylamodiaquine (DEAQ) in both human and mouse, but not in rat microsomes. Regardless, DEAQ was an effective APJ antagonist equipotent to the parent AQ (Figure E in [S1 File](#)). When tested on hepatocytes, AQ showed no signs of cytotoxicity at up to 50µM. Similarly, AQ was not cytotoxic to HRECs at up to 100 µM.

The distribution of AQ in the mouse eye was evaluated after a single intravitreal dose of 50 µg. [Table 2](#) shows that after 24 h AQ is found in the target tissue, the RPE/choroid/sclera section of mouse eyes receiving compound at levels that exceed the cellular EC₅₀ by ~20 fold. The retina contained a modest amount of compound, while the vitreous contained less than was accurately quantifiable via LC/MS. The compound was persistent showing sustained levels in the target tissues 7 d after administration. No detectable levels of AQ were observed in the plasma of mice after 7 d IVT administration.

AQ decreases pathological neovascularization *in vivo*

Despite poor microsomal stability, the combination of balanced solubility and permeability, low protein binding, low cytotoxicity and an equipotent active metabolite led us to advance AQ into *in vivo* efficacy studies. Wild type C57BL/6J mice were subjected to laser-mediated disruption of Bruch’s membrane to induce choroidal neovascularization. One day after laser

Table 2. Distribution of AQ in the mouse eye after intravitreal injection.

Tissue	AQ (ng)		Ratio Tissue mass / Cellular potency	
	24h	168h	24h	168h
Vitreous	BLOQ	BLOQ	ND	ND
Retina	40.0 ± 0.8	45.0 ± 0.9	5	9
RPE/Choroid/Sclera	161.0 ± 2.5	215.0 ± 7.1	20	27

<https://doi.org/10.1371/journal.pone.0202436.t002>

injury, AQ was administered via intravitreal injection at 5.0, 10.0, 25.0, or 50.0 μg . To ensure adequate ocular exposure to AQ, a second injection at the same dose followed six days later (seven days post injury). The CNV lesion size was significantly smaller in the AQ treated eyes than those in vehicle treated eyes 14 days post-laser injury, as monitored *in vivo* by optical coherence tomography (OCT) (Fig 5A–5F). These decreases are comparable to those we have previously obtained using an anti-VEGF164 antibody, which is a murine-optimized equivalent of bevacizumab, the standard of care in humans [73,74]. Confocal images of agglutinin-stained choroidal flatmounts revealed a reduction in CNV lesion size at 10 μg AQ and higher (Fig 5H–5M). Although there was not a statistically significant reduction in the CNV lesion volume compared to the vehicle control in eyes treated with AQ at 5.0 and 10.0 μg , there was a statistically significant decrease in CNV lesion volume at 25.0 μg and an even greater decrease at 50.0 μg compared to the control eyes (Fig 5G). Consistent with the *in vitro* cytotoxicity assays, there were no signs of toxicity to the ocular tissues in the eyes of mice injected with AQ.




Fig 5. *In vivo* efficacy of amodiaquine in mice with CNV. (A–F) Optical coherence tomography (OCT). Representative images of laser-induced CNV lesions (red brackets), showing a significant reduction in size and/or in intensities (black holes) of injury after the treatment with AQ. (H–M) RPE choroidal flat mounts were stained with agglutinin-TRITC conjugate (red) to visualize the CNV lesions by confocal microscopy. Saline treated eyes (A, H). Vehicle (1% DMSO) treated eyes (B, I). AQ treated eyes (C–F, and J–M). AQ doses administered via intravitreal injection are indicated in each panel. Note the reduction in lesion size and the spotted black replacement to the red staining in eyes treated with AQ, indicative of angiogenesis subsiding which showed most effectively at the dose of 50 μg . (G) Quantification of the CNV lesion volume from Z-stack images of choroidal flatmounts stained with agglutinin was made using ImageJ software, and demonstrate a significant reduction in CNV lesion volume after AQ intravitreal injection compared to vehicle-treated controls. $P > 0.01$. Mean \pm SEM, $n = 5$. SEM, standard error of the mean. Statistical significance was determined using ANOVA with Tukey’s multiple comparison’s test.

<https://doi.org/10.1371/journal.pone.0202436.g005>

Discussion

The apelin receptor represents a novel drug target for the treatment of ophthalmic diseases characterized by neovascularization like DR and AMD. *In vitro*, apelin stimulates endothelial cells to proliferate, migrate and to form a tubular network. In preclinical models including zebrafish and mice, apelin has been shown to play a critical role in the development of the retinal vasculature *in vivo*. Importantly, these effects were shown to be independent of VEGF signaling. Consistent with these findings mice genetically deficient in APJ were observed to be protected from laser-induced CNV [48]. This compelling evidence led us to hypothesize that small molecule antagonists of APJ would be an effective therapy for patients who are refractory or non-responders to current standard of care.

Here we report the discovery that 4-chloro-aminoquinolines, typified by the antimalarial drug amodiaquine and related compounds are potent and selective antagonists of APJ. As shown above, a series of related analogs including the NSAID glafenine exerted similar antagonist effects on APJ. This effect appeared biased, blocking only APJ-dependent cAMP signaling, while having no effect on β -arrestin recruitment. When administered intravitreally, amodiaquine penetrated the subretinal layers of the anterior eye where it effectively decreased the size and extent of laser-induced CNV. Despite being rapidly metabolized by CYP450s, amodiaquine achieved persistently high concentrations in the target tissue sufficient to elicit the therapeutic effect. At its highest dose, amodiaquine virtually eliminated the neovascular lesion.

AQ is a non-competitive antagonist of APJ signaling. Whether related 4-chloro-aminoquinolines have the same pharmacology remains to be determined, but the limited data set obtained suggests that APJ antagonism may be a class effect. Indeed, all six related compounds tested share the fundamental 4-chloro-amino-quinoline core, and act as potent, fully efficacious APJ antagonists. A more thorough evaluation of the pharmacology, and structure-activity-relationships of these analogs is necessary to confirm this hypothesis. Such work is beyond the scope of this report, but the facile chemistry, established syntheses, and number of areas of the compound available for substitution, suggest that can be readily conceptualized and handily executed. Further exploration and exploitation of the SAR may also yield novel chemical entities with improved potency, and pharmacological properties.

Our results demonstrate that APJ antagonism appears to block angiogenesis induced by both Ap13 and VEGF, when applied alone and in combination. Based on the data obtained, it does not appear that antagonism of APJ disrupts a synergistic interaction between APJ and VEGF signaling. In consideration of the key role played by apelin in the remodeling of extracellular matrix remodeling [31], and its localized expression to endothelial tip cells [75], it is tempting to hypothesize that the antagonism of APJ prevents angiogenesis by opposing the effects of Ap13 on matrix remodeling. Indeed, we have previously shown that Ap13 suppresses the expression of the matrix forming genes plasminogen activator inhibitor-1 (PAI-1), collagen 1a1, tissue inhibitor of matrix-metalloprotease-1 (TIMP-1), fibronectin and integrin- β , while simultaneously stimulating expression of the matrix degrading enzymes of matrix-metalloprotease-2 (MMP-2) [31]. Under normal development and pathological conditions, the formation and maturation of new blood vessels requires an extracellular matrix environment conducive to the proliferation and migration of endothelial cells [76]. Blocking the effect of Ap13 on matrix remodeling could effectively deny the activated endothelial cell the opportunity to proliferate and migrate, thus mitigating the overall proangiogenic effect of both VEGF and Ap13. Additional studies are required to validate this hypothesis.

AQ is a 4-aminoquinoline that is widely used for both prophylaxis and treatment of malaria [77,78]. This class of antimalarial drugs possess side effects and toxicities ranging from the life threatening to the mundane [79,80,81]. In the US, amodiaquine was withdrawn from the

market because of hepatitis and agranulocytosis [82]. After oral administration, amodiaquine is rapidly metabolized to DEAQ, by the cytochrome P450 enzyme 2C8 [80]. It is this metabolite that is thought to be responsible for these rare, but fatal side effects. Additionally, there are well documented ophthalmologic reactions associated with use of aminoquinolines that must be weighed when considering the use of the compound for CNV. Of these retinopathy is rare, but the most serious [83]. Needless to say, any repurposing of AQ must address the hematologic, hepatic and ophthalmic side effects. Although in our study, amodiaquine persisted in the eye up to seven days post injection, the level of systemic exposure was below the limit of quantitation. This suggests that intravitreal administration of the drug has the potential to ensure delivery to the desired target tissue while limiting systemic exposures that lead to these toxic effects. However, it remains to be seen if the mild, reversible blurring of vision known to occur with long term exposure to amodiaquine, or the more profound retinal toxicities will occur when administered IVT at an effective dose in humans. Further preclinical studies are necessary to thoroughly assess the potential risk of impaired vision and retinopathies before clinical studies are conceived. It is worth noting that there were no signs of overt systemic or ophthalmic toxicity in either the efficacy study or the tissue distribution studies that were executed as part of this study.

In summary, this study validates targeting APJ for the treatment of CNV and provides compelling evidence that AQ, a widely used anti-malarial drug, has a strong anti-angiogenic activity *in vitro* and *in vivo* in a mouse model of AMD. We believe these results provide sufficient evidence to support clinical investigations into the use of amodiaquine alone and in combination with other anti-VEGF drugs. The repurposing or repositioning of AQ in AMD treatment may provide a new therapeutic avenue for patients who fail to respond to existing anti-VEGF therapies. Moreover, as a small molecule, free from composition of matter patent limitations, AQ is a significantly less expensive alternative to the current costly options. This study also lays the foundation for further structure modification of 4-aminoquinolines to discover more optimal analogs for the treatment of CNV.

Materials and methods

Peptides and compounds

Ap13 peptides were purchased from 21st Century Biochemicals, Inc (Marlborough, MA). [¹²⁵I]-Glp65, Nle75, Tyr77-Ap13 was purchased from Perkin Elmer (Waltham, MA). Compounds AQ and 3 were from Spectrum Chemical. Compounds 1, 4–6 were synthesized in house (see **Figure D in S1 File** for synthetic scheme). All other chemicals and reagents were from Sigma-Aldrich (St Louis, MO) except **ML221** which was prepared as described previously [57,84]. The identity and purity of all compounds were confirmed using LC-MS and NMR.

Animal studies

All mice were housed under specific-pathogen-free conditions and handled in accordance with the ARVO statement for Use of Animals in Ophthalmic and Vision Research and the guidelines of the Institutional Animal Care and Use Committee at University of Alabama, Birmingham, EyeCRO, and Sanford Burnham Prebys Medical Discovery Institute at Lake Nona. The animal experiments performed in this study followed protocols that were specifically approved by the Institutional Animal Care and Use Committee of SBP at Lake Nona, The University of Alabama at Birmingham and EyeCRO (Protocol 2017–0160, approved 01/29/2018) was in accordance with AVMA and ARVO guidelines.

Laser-induced CNV model

The laser procedure was undertaken as previously described [85,86]. Briefly, 8-week-old female C57BL/6J mice ($n = 5$ /treatment group) were anesthetized with a mixture of ketamine (80 mg/kg) and xylazine (10 mg/kg) and their pupils dilated with tropicamide (0.5%) and phenylephrine (2.5%). Under a fundus microscope an argon green ophthalmic laser, coupled to a slit lamp set to deliver a 50 ms pulse at 200mW with a 50 μ m spot size, was used to rupture Bruch's membrane in three quadrants of the right eye located approximately 50 μ m from the optic disc at relative positions of 9, 12 and 3 o'clock. The left eye served as an untreated control. Mice were assessed using optical coherence tomography and euthanized 14 days after laser injury. At the time of euthanasia, the eyes were collected, enucleated for histological analysis and fluorescent staining.

Treatment regime

Mice received intravitreal injection (1.0 μ l/eye/injection) into the right eye while the left eye acted as the uninjected control. Animals were randomly assigned to one of six treatment groups each consisting of $n = 5$ mice: saline or vehicle (DMSO), or compounds (0.0–50.0 μ g). On the day of injection the compounds were formulated in 100% DMSO and administered to mice via intravitreal injection immediately after laser injury and again 7 days after laser injury. This second injection ensured sufficient compound would be available for the duration of the experiment.

Optical coherence tomography (OCT)

OCT was performed at the indicated times using the Micron III intraocular imaging system (Phoenix Research Labs, Pleasanton, CA, USA). Before the procedure, eyes were dilated with 1% tropicamide solution (Alcon, Fort Worth, TX, USA) and lubricated with hypromellose ophthalmic demulcent solution (Gonak) (Akorn, Lake Forest, IL, USA). Mice were then placed on a custom heated stage that moves freely to position the mouse eye for imaging. Several horizontal and vertical images were taken per lesion. In addition, gross retinal/choroidal structure, and vascular patterns were examined for possible adverse effects of the test compound or vehicle.

Measurement of lesion volume *ex vivo*

For measuring lesion volume we used a vascular specific dye, Ricinus Communis Agglutinin I, conjugated to rhodamine (Vector Laboratories, Inc.), to label whole flat mounts of RPE/choroid/sclera which were incubated for 30 minutes at room temperature in 1:400 of 10 mM HEPES, 150 mM NaCl and 0.1% Tween 20. The tissues were covered in aqueous mounting medium (VectaShield; Vector Laboratories, Inc.) for observation on a confocal microscope (Olympus DSU-Olympus IX81; Olympus America, Inc., Center Valley, PA). Digital images were captured by using imaging software (SlideBook 4.2; Intelligent Imaging Innovations, Inc., Denver, CO) in a three-dimensional stacked manner to facilitate volumetric analysis from experimental and control samples with identical photomultiplier tube gain settings. The confocal images were then processed identically in experimental and control eyes and measured using ImageJ software. In all CNV studies, animals were randomized and treatments blinded until all analysis is complete. All determinations were performed in at least 5 mice/group.

Tissue distribution study

The distribution of AQ into the vitreous humor, retina, and combined RPE/choroid/sclera of the eyes of mice receiving AQ was evaluated 1 day and 7 days after intravitreal injection. Mice were assigned to groups ($n = 6/\text{group}$) that received either 50 μg compound, or vehicle via intravitreal injection (1 μl volume). One day after injection, $\frac{1}{2}$ of the mice ($n = 3 / \text{group}$) mice were euthanized. The eyes were enucleated and the vitreous humor, retina, and RPE/Choroid/sclera were isolated and snap frozen in liquid N₂. The remaining mice in each treatment group ($n = 3 / \text{group}$) were euthanized and the same tissues collected. The quantity of compound in the tissues ($n = 6 \text{ eyes} / \text{treatment group}$) was measured using LC-MS/MS.

Cell culture

PathHunter™ GPCR Arrestin and cAMP Hunter™ cell lines (DiscoverX Corp., Fremont, CA) were used to assay G-protein-dependent signaling and β -arrestin recruitment to APJ. CHO-K1 cells stably expressing APJ (CHO-K1-APJ) or AT1 (CHO-K1-AT1) with β -arrestin/ β -galactosidase enzyme fragment complementation constructs were maintained in HAM's F-12 medium (Hyclone, Logan, UT) supplemented with 10% FBS, 1X Penicillin-Streptomycin-Glutamine (Invitrogen; Carlsbad, CA), 300 $\mu\text{g}/\text{ml}$ hygromycin (EMD Biosciences, San Diego, CA), and 800 $\mu\text{g}/\text{ml}$ Geneticin (Cellgro, Manassas, VA). Primary Human Retinal Microvascular Endothelial Cells (HRECs) were purchased from Cell Systems (Kirkland, WA) and maintained in Complete Classic Medium with CultureBoost-R™ (Cell Systems). Parent CHO-K1 cells were obtained from ATCC and maintained in HAM's F-12 medium supplemented with 10% FBS, and 1X Penicillin-Streptomycin-Glutamine (Invitrogen; Carlsbad, CA). All cells were incubated at 37°C (5% CO₂, 95% relative humidity) and maintained at less than 70% to 80% confluence (approximately 75,000 cells/cm²). Cell heterologously expressing APJ or AT1 were not used after 10 passages. HRECs were not used in any experiments after five passages.

HREC APJ receptor immunofluorescence labeling

HREC cells were seeded on four chamber Lab-Tek Chambered Coverglass (Thermo Scientific; 1500 cells/chamber) for cell imaging in EGM-2 medium (Lonza) in a 5% CO₂ atmosphere at 37°C for 1 day. Chambers were washed with ice-cold PBS and fixed for 10 min with paraformaldehyde (4%) on ice then washed in PBS containing Triton X-100 (0.2% v/v) for 2 x 20 min to permeabilize the cells. To block nonspecific protein-protein interactions, cells were washed with Odyssey Blocking Buffer and PBS (1:1 v/v) containing 5% BSA for 1 h at room temperature then incubated with rabbit anti-APJ antibodies (Abcam; ab66218, ab84296, ab140508; 1:500 dilution, 2 $\mu\text{g}/\text{ml}$) overnight at +4°C. Goat anti-rabbit Alexa Fluor 594 secondary IgG (H +L; Invitrogen, 1:500 dilution, 4 $\mu\text{g}/\text{ml}$) and DAPI Fluoromount-G (SouthernBiotech) were used for anti-APJ receptor antibodies labeling and cell nuclei staining for confocal fluorescence microscopy detection.

HREC APJ receptor aggregation

1×10^6 HREC cells were labeled with 0.5 μM carboxyfluorescein succinimidyl ester (CFSE) at 37°C for 15 min in EBM-2 media. After incubation cells were centrifuged and resuspended in EGM-2 media then 1700 cells were transferred to a well of Lab-Tek Chambered coverglass and incubated in a 5% CO₂ atmosphere at 37°C overnight. To induce APJ receptor internalization, apelin-13 (100 μM) was applied for 1.5, 3, 6, 12, 30, 60 and 240 min in separate chambers. After incubation the cells were washed, fixed, permeabilized, blocked and labeled with anti-

APJ receptor antibody (ab140508, 1:500 dilution, 2 µg/ml) and secondary Alexa Fluor 594 conjugated antibody and DAPI as stated above.

Confocal fluorescence microscopy

Immunofluorescent images (TIFF; 16 bit) were acquired by laser-scanning confocal microscopy with an A1R confocal microscope (Nikon Instruments) in single channel operation mode. Excitation lasers and emission filters were selected based on staining fluorochromes. Images were obtained with a Plan Apo 60x/1.40 oil objective (Nikon) as optical section Z-stacks. Identical acquisition settings were used for imaging for all time points using the NIS Elements AR software (Nikon). Specific fluorophore intensities were quantified on the Sum Slices Z-projection of the optical sections using ImageJ software (NIH). Area of nucleus of each cells from all time points were selected as region of interest (ROI) based on their DAPI staining.

Cell proliferation and migration assay

The proliferation of HRECs was monitored by the crystal violet assay as described in our previous publication [87]. Briefly, 2,500 cells in 100µL Endothelial Basal Medium (EBM) (Lonza) in the presence of 50 ng/mL recombinant human VEGF165 (Biolegend, San Diego, CA, USA), were incubated in 24-well plates for 24 h followed by 48 h incubation with VEGF, Ap13 and/or the APJ antagonists. At the end of the incubation, cells were fixed in 4% paraformaldehyde in PBS for 15 min and stained in a solution of 0.1% crystal violet (Sigma Aldrich, St. Louis, MO), 10% ethanol for 5 min. After washing three times with PBS, the plates were air-dried and the remaining stain was dissolved in, 10% acetic acid and absorbance measured with a microplate reader at 540 nm.

Migration was determined by the QCM™ chemotaxis 5 µm 96-well cell migration assay (Chemicon International, Inc.) as per the manufacture's protocol. Briefly, HREC migration in response to recombinant human VEGF165 (50 ng/mL) and/or Ap13 (10 nM) was determined alone or in the presence of the APJ antagonist AQ (10 µM). After 16 h, cells that migrated to the basal side of the chamber insert membrane were detached, lysed and detected using CyQuant GR™ dye. Migration is expressed as percent increase in migrated cells compared to untreated cells.

In vitro tube formation assay

In vitro tube formation assays were carried out as previously described [85]. Briefly, near confluent microvascular endothelial cells were pretreated with VEGF (100 ng/ml) for 2 h and then treated for 24 h with test compounds at serial concentrations, as indicated. Cells without VEGF treatment or with VEGF only were used as control. The cells were then detached and plated sparsely (2.5×10^4 /well) on 24-well plates coated with 12.5% (v/v) Matrigel (BD, Franklin Lakes, NJ) and left overnight. The medium was then aspirated and 250 µl/well of 12.5% Matrigel was overlaid on the cells for 2 h to allow the polymerization of Matrigel, followed by addition of 500 µl/well of basal medium MCD131 with 10% fetal calf serum (FCS) for 24 h. The following day, the culture plates were observed under a phase contrast microscope and photographed at random in five fields ($\times 10$). The tubule length (mm/mm²) per microscope field was quantified.

HTS, cAMP assay

All reagents unless otherwise specified are components of the cAMP HitHunter (DiscoverX) kit. Ligand Buffer + 60 µM Forskolin (Cayman Chemical, Ann Arbor, MI) was made fresh on

the day of the experiment and used for the dilution of positive and negative controls as well as all peptides. CHO-K1-APJ cells were dispensed into a 1536-well tissue culture microplate (Corning, Corning, NY) using a Multidrop at a seeding density of 1,000 cells/well and returned to the incubator. The next day, the cell culture media was removed and replaced with 15 μ /well of assay buffer (1X HBSS, 10 mM HEPES) containing anti-cAMP antibody (DiscoverRx). Using the Janus Automated Workstation (Perkin Elmer), 5 μ l of Ap13, ligand buffer (vehicle, 1X HBSS, 10 mM HEPES, 0.1% BSA), or peptide (10-point concentrations) were added to all wells, and subsequently incubated at 37°C for 30 min. A working solution of ED/Lysis/CL substrate (20 μ l/well) was added to all wells and incubated for 1 h at room temperature in the dark prior to a final addition of EA Reagent (20 μ l/well). Plates were incubated at room temperature in the dark for 3 hours prior to chemiluminescence detection on an EnVision (Perkin Elmer) using a counting time of 1 s/well.

APJ and AT1 β -arrestin recruitment assays

CHO-K1 cells engineered to over-express APJ or AT1, and β -arrestin were removed from flasks using TrypLE Select (1X), no phenol red (Life Technologies, Grand Island, NY), centrifuged, and resuspended in CP2 Reagent (DiscoverRx, Fremont, CA). Cells were counted using a Countess Automated Cell Counter (Invitrogen, Carlsbad, CA) and 5,000 cells/well were plated in a 384-well tissue culture treated microplate (Corning, Corning, NY). All plates were incubated overnight at 37°C, 5% CO₂ in a final volume of 25 μ l/well. Following incubation, 5 μ l of peptides (10-point concentrations) and controls prepared in ligand buffer (1X HBSS, 10 mM HEPES, 0.1% BSA) were added to cells and incubated at 37°C for 1.5 h. Using a Multidrop Combi Reagent Dispenser (Thermo Scientific), 12 μ l of Detection Reagent (DiscoverRx) comprised of substrate and co-factors was added to all wells and incubated at room temperature in the dark for 1 h. Chemiluminescent signal was detected on an EnVision Multi-label plate reader (Perkin Elmer) using a counting time of 1 s/well. The robustness of data from each screening plate and run was monitored by Z' and Signal Window calculation [88].

Radioligand competition binding assay

Prior to the initiation of the assay, soaking buffer (50 mM Tris-HCl pH 7.5, 0.5% polyethylenimine), assay buffer (25 mM HEPES pH 7.5, 10 mM MgCl₂, 1mM CaCl₂, 0.5% BSA, protease inhibitor), and wash buffer (50 mM Tris-HCl pH 7.5, 0.5% BSA) were prepared. Soaking buffer (300 μ l/well) was added to a 96-well GF/C filter plate (MultiScreen Harvest plate, Millipore) and left to equilibrate at room temperature for 3 h. Briefly, 25 μ l peptide (8-point concentrations), 25 μ l of 0.2 nM [¹²⁵I] Glp65, Nle75, Tyr77-Ap13 (Perkin Elmer), and 150 μ l APJ membrane (Perkin Elmer) diluted 1:150 in assay buffer, were added to a 96-well HB OptiPlate (Perkin Elmer) and incubated at room temperature for 45 min. Following incubation, contents were transferred from the OptiPlate to the pre-wet GF/C filter plate, and immediately underwent vacuum filtration. The filter plate was washed five times with 200 μ l ice cold wash buffer and left at room temperature overnight to equilibrate. The next day, 20 μ l scintillation liquid (Microscint 20, Perkin Elmer) was added and radioactivity quantified using a TopCount NXT (Perkin Elmer) microplate scintillation and luminescence counter.

Competition binding analysis for the agonist [¹²⁵I]-Glp65, Nle75, Tyr7-Ap13 by SBI-612 in the absence and presence of Ap13 (100 nM) was performed according to the equation (Graph-Pad Prism version 7):

$$Y = Bottom + \frac{Top - Bottom}{1 + 10^{(X - LogIC_{50})}} \quad (1)$$

where Y represents specific binding of the radioligand, Top is the specific binding of the radioligand in the absence of competing ligand, Bottom is the specific binding of the radioligand equivalent to nonspecific binding, IC_{50} is the concentration of competing ligand that produces radioligand binding halfway between the Top and Bottom, and X is the logarithm of the concentration of the competing ligand. The Cheng & Prusoff equation was used to convert IC_{50} estimates to equilibrium dissociation constants [89].

Microsome stability assay

Hepatic microsomes stability assays were performed as reported before [90]. Briefly, 3 μ L of 25 μ M compound solution in acetonitrile were incubated with 123 μ L of mouse, human or rat liver microsomes (Xenotech, Kansas City, KS). After preincubation at 37°C for 10 min, enzyme reactions were initiated by adding 120 μ L of NADPH-generating system (2 mM NADP⁺, 10 mM glucose-6-phosphate, 0.4 U/ml glucose-6-phosphate dehydrogenase, and 5 mM MgCl₂) in the presence of 100 mM potassium phosphate buffer (pH 7.4). The final concentration of each model compound used was 1 μ M. The microsomal concentrations used were 1.0 mg/mL. Compounds were incubated in microsomes for 0, 5, 15, 30 and 60 min. The reactions were stopped by the addition of ice cold ACN and the reaction mixtures were centrifuged at 10,000g for 10 min before the supernatant was removed for analysis. 10 μ L of the resulting extract were injected on a Thermo HPLC system equipped with PAL CTC plate sampler (96-well plate), Dionex Ultimate 3000 binary pump (flow rate at 0.600 mL/min), Dionex Ultimate 3000 thermostatted column compartment (temperature at 40°C), Thermo Endura Mass Spectrometer (ESI source), using a Thermo Scientific Accucore C18 (2.6 μ M, 2.1 x 50 mm) column. A gradient was run starting at 95% H₂O (0.1% formic acid) and 5% ACN (0.1% formic acid) during the first 0.5 min, then under gradient condition of 5–100% ACN (0.1% formic acid) from minute 0.5 to 3.5, finishing at 95% H₂O (0.1% formic acid) and 5% ACN (0.1% formic acid) over 0.5 min, with another 1 min at 95:5 to re-equilibrate. For quantification, fresh neat samples of AQ and DEAQ were solubilized in DMSO then spiked into water to generate calibration curve.

Cytotoxicity

Fa2N-4 immortalized human hepatocytes (Xenotech) or HREC cells were grown to subconfluency in wells of a 96-well plate and exposed to different concentrations of compounds for 24 h after which the cells were washed and the media and compounds replaced. The cells were returned to the incubator for another 24 h. The extent of cell death (cell lysis) was determined by ATP-Lite reagent (Perkin-Elmer).

Curve fit and statistical analysis

All concentration response curves were analyzed to determine EC_{50} and E_{max} using the following equation:

$$Y = \frac{100}{(1 + 10^{(\text{Log}EC_{50}-X) * \text{HillSlope}})} \quad (2)$$

where Y = the normalized response (0–100%), X is the log of concentration of compound tested, and the Hill slope is set equal to 1.

Except for the primary assay in the HTS campaign, all experiments were repeated at least three times. Results are expressed as mean \pm SEM. The Mann-Whitney test was used to determine statistical significance of the densitometry data of Western blot analysis. Unpaired two-

tailed Student's *t*-test was performed for the significance of the results of ELISA and *in vitro* tubule formation assay. ANOVA was used to determine the significance *in vivo* CNV models using the Tukey post-hoc test for multiple comparisons. Curve fit and statistical analyses was performed using Prism 7 (GraphPad Software, Inc., La Jolla, CA) with $p < 0.05$ considered statistically significant. $T_{1/2}$ was calculated using the best fit curve resulting from non-linear (human) or linear (mouse and rat) regression analyses using Prism 7.

Synthesis of aminoquinolines

The synthesis of aminoquinolines is shown in Figure F in [S1 File](#). 4,7-dichloroquinoline (101 mg, 0.51 mmol) and ethyl-4-aminobenzoate (87 mg, 0.53 mmol) were heated in ethanol at 80°C 45 minutes then stirred at room temperature. The solids were filtered to provide ethyl 4-((7-chloroquinolin-4-yl)amino)benzoate hydrochloride (147 mg, 79%). The ester (143 mg, 0.39 mmol) was hydrolyzed with lithium hydroxide (32 mg, 1.34 mmol) in water (1 mL) and THF (4 mL) at room temperature. The mixture was partitioned with ethyl acetate and water. The aqueous phase was acidified with conc. HCl to precipitate 4-((7-chloroquinolin-4-yl)amino)benzoic acid hydrochloride (131 mg, 99%). The acid (20 mg, 0.06 mmol) was activated with HATU (30 mg, 0.08 mmol) and triethylamine (0.045 mL, 0.32 mmol) in THF for 30 minutes prior to the introduction of excess ammonia (0.24 mL, 0.5 M in THF, 0.12 mmol). After stirring overnight the mixture was diluted with water, treated with sodium bicarbonate, and the product was extracted with ethyl acetate. The crude material was purified by reverse phase HPLC to provide 4-((7-chloroquinolin-4-yl)amino)benzamide (16 mg, 90%). Proton NMR spectra for synthesized analogs are shown in Figures G–J in [S1 File](#).

Supporting information

S1 File. Supporting information for the anti-malarial drug, amodiaquine, is an apelin-receptor antagonist that blocks angiogenesis *in vitro* and *in vivo*. (DOCX). Table A. Results of quantitative PCR showing the endogenous mRNA levels of APJ in HRECs compared to heterologously expressed APJ in CHO-K1 cells and parental cells lacking APJ. Results presented as relative expression level of APJ normalized to endogenous calibrator target (GAPDH), and as a relative percent expression normalized to the CHO-K1 cells heterologously overexpressing human APJ. **Figure A. Human retinal endothelial cells (HREC) express APJ.** (A, B, C) APJ protein was detected and visualized in HRECs by immunocytochemistry using the anti-APJ antibodies indicated, and an Alexa488 conjugated secondary antibody. (D) A control experiment in which the primary anti-APJ antibody was omitted shows the specificity of these antibodies for APJ. **Figure B. Ap13 does not synergize with VEGF to induce HREC tube formation.** HREC cells were exposed to both Ap13 alone (black bars) and in combination with VEGF (10 ng/mL, grey bars). Increasing concentrations of Ap13 up to 100 nM had no observable synergistic effect with VEGF compared to AP13 alone. There was no statistically significant difference between either treatment ($p > 0.5$, by Student's *t*-test). **Figure C. ML221 blocks VEGF-induced HREC tube formation.** Data plotted is the mean \pm SEM length of endothelial tubes measured in micrometers (μm), normalized to vehicle control. Mean and SEM are calculated from an experiment that was performed twice with each treatment condition tested in triplicate ($n = 3$). NS = not significant; ** = $p < 0.01$; *** = $p < 0.001$ vs vehicle; † = $p < 0.0001$ compared to cells incubated with VEGF alone (100 ng/mL) as determined by ANOVA with Tukey's multiple comparison test. **Figure D. Metabolism of AQ to DEAQ by hepatic microsomes.** The conversion of AQ to the metabolite desethylaminoquinoline (DEAQ) was monitored *in vitro* using (A) mouse, (B) human and (C) rat hepatic microsomes. The consumption of AQ and a production of DEAQ was measured by quantitative LC-MS/

MS using internal standards and a standard curve for both AQ and DEAQ. Data points represent the mean \pm SEM ng/mL of each compound from an experiment performed in duplicate. Curves represent the best fit non-linear regression analysis for AQ and linear regression analysis for DEAQ as described in materials and methods, using GraphPad Prism7. **Figure E. Concentration response of DEAQ, the primary human metabolite of AQ, at APJ.** Data are mean \pm SEM (n = 3). Curve represents the best fit non-linear regression analysis calculated using a 4-parameter logistic with GraphPad Prism7. **Figure F. Synthetic scheme depicting the facile synthesis of aminoquinolines used in this study.** Conditions: i) ethyl-4-aminobenzoate, EtOH, 80°C; ii) LiOH, H₂O, THF; iii) HATU, NH₃, Et₃N. **Figure G. Proton NMR spectra for 1. 4-((7-chloroquinolin-4-yl)amino)benzamide.** ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.28 (s, 1H), 8.56 (d, *J* = 5.2 Hz, 1H), 8.41 (d, *J* = 9.0 Hz, 1H), 7.95–7.88 (m, 3H), 7.61 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.41 (d, *J* = 8.6 Hz, 2H), 7.26 (s, 1H), 7.15 (d, *J* = 5.3 Hz, 1H). LRMS (ESI+ve): Calculated for C₁₆H₁₂ClN₃O, [M+H] = 298.07, observed [M+H] = 298.21. **Figure H. Proton NMR spectra for 4. 7-chloro-N-(4-methoxyphenyl)quinolin-4-amine.** ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.96 (s, 1H), 8.42 (d, *J* = 9.1 Hz, 1H), 8.39 (d, *J* = 5.4 Hz, 1H), 7.86 (d, *J* = 2.2 Hz, 1H), 7.54 (dd, *J* = 9.0, 2.3 Hz, 1H), 7.28 (d, *J* = 8.8 Hz, 2H), 7.02 (d, *J* = 8.8 Hz, 2H), 6.62 (d, *J* = 5.4 Hz, 1H), 3.79 (s, 3H). LRMS (ESI+ve): Calculated for C₁₆H₁₃ClN₂O, [M+H] = 285.08, observed [M+H] = 285.22. **Figure I. Proton NMR spectra for 5. 2-((7-chloroquinolin-4-yl)amino)benzoic acid.** ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.63 (d, *J* = 9.1 Hz, 1H), 8.53 (d, *J* = 6.7 Hz, 1H), 8.10 (d, *J* = 8.4 Hz, 2H), 7.88 (d, *J* = 8.9 Hz, 1H), 7.78 (t, *J* = 7.6 Hz, 1H), 7.64 (d, *J* = 7.9 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 1H), 6.72 (d, *J* = 6.6 Hz, 1H). LRMS (ESI+ve): Calculated for C₁₆H₁₁ClN₂O₂, [M+H] = 299.06, observed [M+H] = 299.19. **Figure J. Proton NMR for 6. (2-((7-chloroquinolin-4-yl)amino)phenyl)(morpholino) methanone.** ¹H NMR (500 MHz, Chloroform-*d*) δ 8.54 (d, *J* = 5.3 Hz, 1H), 7.96 (d, *J* = 2.1 Hz, 1H), 7.85 (d, *J* = 9.0 Hz, 1H), 7.62 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.42 (dd, *J* = 8.9, 2.2 Hz, 1H), 7.38 (ddd, *J* = 8.4, 7.4, 1.6 Hz, 1H), 7.26 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.10 (d, *J* = 5.3 Hz, 1H), 7.06 (td, *J* = 7.6, 1.1 Hz, 1H), 3.58 (s, 8H). LRMS (ESI+ve): Calculated for C₂₀H₁₈ClN₃O₂, [M+H] = 368.12, observed [M+H] = 368.32. (DOCX)

Acknowledgments

We thank Kyle C. Ziegler for editorial assistance.

Author Contributions

Conceptualization: Maria B. Grant.

Data curation: Khandaker Siddiquee, Andras Szabo, Stefan Vasile, Patrick R. Maloney, Daniela B. Divlianska, Satyamaheshwar Peddibhotla, Camilo J. Morfa, Paul Hershberger, Rebecca Falter, Robert Williamson, David B. Terry, Rafal Farjo, Xiaping Qi, Judith Quigley, Michael E. Boulton, Maria B. Grant.

Formal analysis: Danielle McAnally, Khandaker Siddiquee, Andras Szabo, Stefan Vasile, Patrick R. Maloney, Daniela B. Divlianska, Satyamaheshwar Peddibhotla, Camilo J. Morfa, Paul Hershberger, Rebecca Falter, Robert Williamson, David B. Terry, Rafal Farjo, Anthony B. Pinkerton, Xiaping Qi, Judith Quigley, Michael E. Boulton.

Investigation: Ahmed Gomaa, Rafal Farjo, Michael E. Boulton, Maria B. Grant, Layton H. Smith.

Project administration: Camilo J. Morfa.

Writing – original draft: Anthony B. Pinkerton.

Writing – review & editing: Ahmed Gomaa, Layton H. Smith.

References

1. Pascolini D, Mariotti SP (2012) Global estimates of visual impairment: 2010. *The British journal of ophthalmology* 96: 614–618. <https://doi.org/10.1136/bjophthalmol-2011-300539> PMID: 22133988
2. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. (2004) Global data on visual impairment in the year 2002. *Bulletin of the World Health Organization* 82: 844–851. PMID: 15640920
3. Varma R, Macias GL, Torres M, Klein R, Pena FY, Azen SP (2007) Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino Eye Study. *Ophthalmology* 114: 1332–1340. <https://doi.org/10.1016/j.ophtha.2006.10.023> PMID: 17306879
4. (2013) Prevalence of Adult Vision Impairment and Age-Related Eye Diseases in America. NEI Office of Science Communications, Public Liaison, and Education.
5. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, et al. (1999) Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. *Investigative ophthalmology & visual science* 40: 182–189.
6. Nowak JZ (2006) Age-related macular degeneration (AMD): pathogenesis and therapy. *Pharmacological reports: PR* 58: 353–363. PMID: 16845209
7. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J (2004) Retinal ischemia: mechanisms of damage and potential therapeutic strategies. *Progress in retinal and eye research* 23: 91–147. <https://doi.org/10.1016/j.preteyeres.2003.12.001> PMID: 14766318
8. Wilkinson-Berka JL, Rana I, Armani R, Agrotis A (2013) Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. *Clinical science* 124: 597–615. <https://doi.org/10.1042/CS20120212> PMID: 23379642
9. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. *Retina* 26: 859–870. <https://doi.org/10.1097/O1.iae.0000242842.14624.e7> PMID: 17031284
10. Yu L, Liang XH, Ferrara N (2011) Comparing protein VEGF inhibitors: In vitro biological studies. *Biochemical and biophysical research communications* 408: 276–281. <https://doi.org/10.1016/j.bbrc.2011.04.014> PMID: 21501594
11. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. *Ophthalmology* 119: 1399–1411. <https://doi.org/10.1016/j.ophtha.2012.04.015> PMID: 22578446
12. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmology* 113: 363–372 e365. <https://doi.org/10.1016/j.ophtha.2005.11.019> PMID: 16458968
13. Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. *Retina* 26: 352–354. PMID: 16508438
14. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. *Ophthalmology* 113: 1695 e1691-1615. <https://doi.org/10.1016/j.ophtha.2006.05.064> PMID: 17011951
15. Spaide RF, Laud K, Fine HF, Klancnik JM Jr., Meyerle CB, Yannuzzi LA, et al. (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina* 26: 383–390. <https://doi.org/10.1097/O1.iae.0000238561.99283.0e> PMID: 16603955
16. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. *Nature reviews Cancer* 8: 592–603. <https://doi.org/10.1038/nrc2442> PMID: 18650835
17. van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW (2015) The great escape; the hallmarks of resistance to antiangiogenic therapy. *Pharmacological reviews* 67: 441–461. <https://doi.org/10.1124/pr.114.010215> PMID: 25769965
18. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, et al. (2008) Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. *PloS one* 3: e3554. <https://doi.org/10.1371/journal.pone.0003554> PMID: 18978936
19. Tokunaga CC, Mitton KP, Dailey W, Massoll C, Roumayah K, Guzman E, et al. (2014) Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. *Investigative ophthalmology & visual science* 55: 1884–1892.

20. Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, et al. (2005) Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. *The American journal of pathology* 167: 1451–1459. [https://doi.org/10.1016/S0002-9440\(10\)61231-X](https://doi.org/10.1016/S0002-9440(10)61231-X) PMID: 16251428
21. Ehlken C, Jungmann S, Bohringer D, Agostini HT, Junker B, Pielen A (2014) Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. *Eye* 28: 538–545. <https://doi.org/10.1038/eye.2014.64> PMID: 24722504
22. Yang S, Zhao J, Sun X (2016) Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. *Drug design, development and therapy* 10: 1857–1867. <https://doi.org/10.2147/DDDT.S97653> PMID: 27330279
23. Fan X, Zhou N, Zhang X, Mukhtar M, Lu Z, Fang J, et al. (2003) Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. *Biochemistry* 42: 10163–10168. <https://doi.org/10.1021/bi030049s> PMID: 12939143
24. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. (2000) Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. *J Biol Chem* 275: 21061–21067. <https://doi.org/10.1074/jbc.M908417199> PMID: 10777510
25. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, et al. (2003) Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. *J Neurochem* 84: 1162–1172. PMID: 12603839
26. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. (2000) Characterization of apelin, the ligand for the APJ receptor. *J Neurochem* 74: 34–41. PMID: 10617103
27. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. (1998) Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. *Biochem Biophys Res Commun* 251: 471–476. <https://doi.org/10.1006/bbrc.1998.9489> PMID: 9792798
28. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem* 277: 14838–14843. <https://doi.org/10.1074/jbc.M200581200> PMID: 11815627
29. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP (2001) [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. *Br J Pharmacol* 132: 1255–1260. <https://doi.org/10.1038/sj.bjp.0703939> PMID: 11250876
30. Masri B, Lahlou H, Mazarguil H, Knibiehler B, Audigier Y (2002) Apelin (65–77) activates extracellular signal-regulated kinases via a PTX-sensitive G protein. *Biochem Biophys Res Commun* 290: 539–545. <https://doi.org/10.1006/bbrc.2001.6230> PMID: 11779205
31. Siddiquee K, Hampton J, Khan S, Zadory D, Gleaves L, Vaughan DE, et al. (2011) Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. *Journal of hypertension* 29: 724–731. <https://doi.org/10.1097/HJH.0b013e32834347de> PMID: 21358420
32. Chandrasekaran B, Dar O, McDonagh T (2008) The role of apelin in cardiovascular function and heart failure. *Eur J Heart Fail* 10: 725–732. <https://doi.org/10.1016/j.ejheart.2008.06.002> PMID: 18583184
33. Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, et al. (2008) Vascular effects of apelin *in vivo* in man. *J Am Coll Cardiol* 52: 908–913. <https://doi.org/10.1016/j.jacc.2008.06.013> PMID: 18772060
34. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, et al. (2010) Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. *Circulation* 121: 1818–1827. <https://doi.org/10.1161/CIRCULATIONAHA.109.911339> PMID: 20385929
35. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, et al. (2007) Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. *Circ Res* 101: e32–42. <https://doi.org/10.1161/CIRCRESAHA.107.158659> PMID: 17673668
36. O'Shea M, Hansen MJ, Tatemoto K, Morris MJ (2003) Inhibitory effect of apelin-12 on nocturnal food intake in the rat. *Nutr Neurosci* 6: 163–167. <https://doi.org/10.1080/1028415031000111273> PMID: 12793520
37. Sunter D, Hewson AK, Dickson SL (2003) Intracerebroventricular injection of apelin-13 reduces food intake in the rat. *Neurosci Lett* 353: 1–4. PMID: 14642423
38. Mitra A, Katovich MJ, Mecca A, Rowland NE (2006) Effects of central and peripheral injections of apelin on fluid intake and cardiovascular parameters in rats. *Physiol Behav* 89: 221–225. <https://doi.org/10.1016/j.physbeh.2006.06.006> PMID: 16839572

39. Roberts EM, Newson MJ, Pope GR, Landgraf R, Lolait SJ, O'Carroll AM (2009) Abnormal fluid homeostasis in apelin receptor knockout mice. *J Endocrinol* 202: 453–462. <https://doi.org/10.1677/JOE-09-0134> PMID: 19578099
40. Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillon W, et al. (2002) The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. *Biochem Biophys Res Commun* 291: 1208–1212. <https://doi.org/10.1006/bbrc.2002.6575> PMID: 11883945
41. Li F, Li L, Qin X, Pan W, Feng F, Chen F, et al. (2008) Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1. *Front Biosci* 13: 3786–3792. PMID: 18508473
42. Liu C, Su T, Li F, Li L, Qin X, Pan W, et al. (2010) PI3K/Akt signaling transduction pathway is involved in rat vascular smooth muscle cell proliferation induced by apelin-13. *Acta Biochim Biophys Sin (Shanghai)* 42: 396–402.
43. Tang SY, Xie H, Yuan LQ, Luo XH, Huang J, Cui RR, et al. (2007) Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways. *Peptides* 28: 708–718. <https://doi.org/10.1016/j.peptides.2006.10.005> PMID: 17109997
44. Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA (2006) Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. *Dev Biol* 296: 177–189. <https://doi.org/10.1016/j.ydbio.2006.04.452> PMID: 16750822
45. Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, et al. (2004) Apelin is a novel angiogenic factor in retinal endothelial cells. *Biochem Biophys Res Commun* 325: 395–400. <https://doi.org/10.1016/j.bbrc.2004.10.042> PMID: 15530405
46. Kasai A, Shintani N, Kato H, Matsuda S, Gomi F, Haba R, et al. (2008) Retardation of retinal vascular development in apelin-deficient mice. *Arterioscler Thromb Vasc Biol* 28: 1717–1722. <https://doi.org/10.1161/ATVBAHA.108.163402> PMID: 18599802
47. Kalin RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, Brandli AW (2007) Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. *Dev Biol* 305: 599–614. <https://doi.org/10.1016/j.ydbio.2007.03.004> PMID: 17412318
48. Hara C, Kasai A, Gomi F, Satooka T, Sakimoto S, Nakai K, et al. (2013) Laser-induced choroidal neovascularization in mice attenuated by deficiency in the apelin-APJ system. *Investigative ophthalmology & visual science* 54: 4321–4329.
49. Kasai A, Ishimaru Y, Kinjo T, Satooka T, Matsumoto N, Yoshioka Y, et al. (2010) Apelin Is a Crucial Factor for Hypoxia-Induced Retinal Angiogenesis. *Arterioscler Thromb Vasc Biol*.
50. Muto J, Shirabe K, Yoshizumi T, Ikegami T, Aishima S, Ishigami K, et al. (2014) The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma. *Anticancer research* 34: 5313–5320. PMID: 25275024
51. Eyries M, Siegfried G, Ciumas M, Montagne K, Agrapart M, Lebrin F, et al. (2008) Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. *Circ Res* 103: 432–440. <https://doi.org/10.1161/CIRCRESAHA.108.179333> PMID: 18617693
52. Kidoya H, Naito H, Takakura N (2010) Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. *Blood* 115: 3166–3174. <https://doi.org/10.1182/blood-2009-07-232306> PMID: 20185589
53. Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, Yano T, et al. (2008) Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. *EMBO J* 27: 522–534. <https://doi.org/10.1038/sj.emboj.7601982> PMID: 18200044
54. Kojima Y, Quertermous T (2008) Apelin-APJ signaling in retinal angiogenesis. *Arterioscler Thromb Vasc Biol* 28: 1687–1688. <https://doi.org/10.1161/ATVBAHA.108.174847> PMID: 18799795
55. Takakura N, Kidoya H (2009) Maturation of blood vessels by haematopoietic stem cells and progenitor cells: involvement of apelin/APJ and angiotensin/Tie2 interactions in vessel caliber size regulation. *Thromb Haemost* 101: 999–1005. PMID: 19492139
56. Khan P, Maloney PR, Hedrick M, Gosalia P, Milewski M, Li L, et al. (2010) Functional Agonists of the Apelin (APJ) Receptor. *Probe Reports from the NIH Molecular Libraries Program*. Bethesda (MD).
57. Maloney PR, Khan P, Hedrick M, Gosalia P, Milewski M, Li L, et al. (2012) Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor. *Bioorganic & medicinal chemistry letters* 22: 6656–6660.
58. Ishimaru Y, Shibagaki F, Yamamuro A, Yoshioka Y, Maeda S (2017) An apelin receptor antagonist prevents pathological retinal angiogenesis with ischemic retinopathy in mice. *Scientific reports* 7: 15062. <https://doi.org/10.1038/s41598-017-15602-3> PMID: 29118394

59. Bassoni DL, Jafri Q, Sastry S, Mathrubutham M, Wehrman TS (2012) Characterization of G-protein coupled receptor modulators using homogeneous cAMP assays. *Methods in molecular biology* 897: 171–180. https://doi.org/10.1007/978-1-61779-909-9_8 PMID: 22674165
60. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. (1993) A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. *Gene* 136: 355–360. PMID: 8294032
61. Shimizu Y, Nakayama M (2017) Discovery of Novel Gq-Biased LPA1 Negative Allosteric Modulators. *SLAS discovery* 22: 859–866. <https://doi.org/10.1177/2472555217691719> PMID: 28346103
62. Arunlakshana O, Schild HO (1997) Some quantitative uses of drug antagonists. 1958. *British journal of pharmacology* 120: 151–161; discussion 148–150. <https://doi.org/10.1111/j.1476-5381.1997.tb06793.x> PMID: 9142403
63. McLean DL, Kim J, Kang Y, Shi H, Atkins GB, Jain MK, et al. (2012) Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells—brief report. *Arteriosclerosis, thrombosis, and vascular biology* 32: 2640–2643. <https://doi.org/10.1161/ATVBAHA.112.300317> PMID: 22995518
64. Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus Perez V, et al. (2011) Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. *Arteriosclerosis, thrombosis, and vascular biology* 31: 814–820. <https://doi.org/10.1161/ATVBAHA.110.219980> PMID: 21233449
65. Kleinz MJ, Skepper JN, Davenport AP (2005) Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. *Regul Pept* 126: 233–240. <https://doi.org/10.1016/j.regpep.2004.10.019> PMID: 15664671
66. Chen L, Tao Y, Feng J, Jiang YR (2015) Apelin Protects Primary Rat Retinal Pericytes from Chemical Hypoxia-Induced Apoptosis. *Journal of ophthalmology* 2015: 186946. <https://doi.org/10.1155/2015/186946> PMID: 26491547
67. Stehlik C, Kroismayr R, Dorfleutner A, Binder BR, Lipp J (2004) VIGR—a novel inducible adhesion family G-protein coupled receptor in endothelial cells. *FEBS letters* 569: 149–155. <https://doi.org/10.1016/j.febslet.2004.05.038> PMID: 15225624
68. Goodman OB Jr., Krupnick JG, Santini F, Gurevich VV, Penn RB, Gagnon AW, et al. (1996) Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. *Nature* 383: 447–450. <https://doi.org/10.1038/383447a0> PMID: 8837779
69. Laporte SA, Miller WE, Kim KM, Caron MG (2002) beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binding site in beta 2-adaptin. *The Journal of biological chemistry* 277: 9247–9254. <https://doi.org/10.1074/jbc.M108490200> PMID: 11777907
70. Chung TDY, Terry DB, Smith LH (2004) In Vitro and In Vivo Assessment of ADME and PK Properties During Lead Selection and Lead Optimization—Guidelines, Benchmarks and Rules of Thumb. In: Sitampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M et al., editors. *Assay Guidance Manual*. Bethesda (MD).
71. Smith DA, Di L, Kerns EH (2010) The effect of plasma protein binding on *in vivo* efficacy: misconceptions in drug discovery. *Nature reviews Drug discovery* 9: 929–939. <https://doi.org/10.1038/nrd3287> PMID: 21119731
72. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. *The Journal of pharmacology and experimental therapeutics* 300: 399–407. PMID: 11805197
73. Irani Y, Scotney P, Nash A, Williams KA (2016) Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions. *Investigative ophthalmology & visual science* 57: 586–591.
74. Sulaiman RS, Merrigan S, Quigley J, Qi X, Lee B, Boulton ME, et al. (2016) A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy. *Scientific reports* 6: 25509. <https://doi.org/10.1038/srep25509> PMID: 27148944
75. Del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, et al. (2010) Identification and functional analysis of endothelial tip cell-enriched genes. *Blood*.
76. Pepper MS (2001) Extracellular proteolysis and angiogenesis. *Thrombosis and haemostasis* 86: 346–355. PMID: 11487024
77. Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, et al. (2012) Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride. *Journal of pharmaceutical sciences* 101: 4390–4401. <https://doi.org/10.1002/jps.23312> PMID: 22949374
78. Olliaro P, Mussano P (2003) Amodiaquine for treating malaria. *The Cochrane database of systematic reviews*: CD000016. <https://doi.org/10.1002/14651858.CD000016> PMID: 12804382
79. Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, Singer CR, et al. (1986) Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. *Lancet* 1: 411–414. PMID: 2868340

80. Nefitel KA, Woodtly W, Schmid M, Frick PG, Fehr J (1986) Amodiaquine induced agranulocytosis and liver damage. *British medical journal* 292: 721–723. PMID: [3082410](#)
81. Wittes R (1987) Adverse reactions to chloroquine and amodiaquine as used for malaria prophylaxis: a review of the literature. *Canadian family physician Medecin de famille canadien* 33: 2644–2649. PMID: [21264010](#)
82. (1985) Revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant *Plasmodium falciparum*. *MMWR Morbidity and mortality weekly report*. 1985/04/12 ed: Centers for Disease Control and Prevention. pp. 185–190, 195.
83. Hirst LW, Sanborn G, Green WR, Miller NR, Heath WD (1982) Amodiaquine ocular changes. *Archives of ophthalmology* 100: 1300–1304. PMID: [7103815](#)
84. Maloney PR, Khan P, Hedrick M, Gosalia P, Milewski M, Li L, et al. (2010) Functional antagonists of the Apelin (APJ) receptor. *Probe Reports from the NIH Molecular Libraries Program*. Bethesda (MD).
85. Liu L, Qi X, Chen Z, Shaw L, Cai J, Smith LH, et al. (2013) Targeting the IRE1 α /XBP1 and ATF6 arms of the unfolded protein response enhances VEGF blockade to prevent retinal and choroidal neovascularization. *The American journal of pathology* 182: 1412–1424. <https://doi.org/10.1016/j.ajpath.2012.12.020> PMID: [23395094](#)
86. Qi X, Cai J, Ruan Q, Liu L, Boye SL, Chen Z, et al. (2012) gamma-Secretase inhibition of murine choroidal neovascularization is associated with reduction of superoxide and proinflammatory cytokines. *Investigative ophthalmology & visual science* 53: 574–585.
87. Song C, Mitter SK, Qi X, Beli E, Rao HV, Ding J, et al. (2017) Oxidative stress-mediated NFkappaB phosphorylation upregulates p62/SQSTM1 and promotes retinal pigmented epithelial cell survival through increased autophagy. *PloS one* 12: e0171940. <https://doi.org/10.1371/journal.pone.0171940> PMID: [28222108](#)
88. Iversen PW, Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ, et al. (2004) HTS Assay Validation. In: Sittampalam GS, Gal-Edd N, Arkin M, Auld D, Austin C et al., editors. *Assay Guidance Manual*. Bethesda (MD).
89. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K_i) and the concentration of an inhibitor which causes 50 per cent inhibition (I_m) of an enzymatic reaction. *Biochem Pharmacol* 22: 3099–3108. PMID: [4202581](#)
90. Peddibhotla S, Hedrick MP, Hershberger P, Maloney PR, Li Y, Milewski M, et al. (2013) Discovery of ML314, a Brain Penetrant Non-Peptidic beta-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor. *ACS medicinal chemistry letters* 4: 846–851. <https://doi.org/10.1021/ml400176n> PMID: [24611085](#)